Biotech Values

[DewDiligence]

ADXS inks deal with Stendhal to commercialize Axalimogene Filolisbac (a/k/a ADXS-HPV) in Latin America:

http://finance.yahoo.com/news/advaxis-axalimogene-filolisbac-developed-commercialized-130500577.html

Under the terms of the Agreement, Stendhal will pay $10 million toward the expenses of AIM2CERV, a planned global Phase 3 clinical trial in women with high-risk, locally advanced cervical cancer. This payment covers a significant portion of the total planned study costs.

Stendhal will also work with Advaxis to complete the clinical trial of axalimogene filolisbac in Mexico, Brazil, Colombia, and other investigational sites in Latin American countries. Additionally, Stendhal will manage the regulatory approval process, promotion, commercialization and market access for axalimogene filolisbac in these markets. Advaxis and Stendhal will share profits on a pre-determined basis.